151
Participants
Start Date
June 30, 2020
Primary Completion Date
March 31, 2028
Study Completion Date
March 31, 2029
SX-682
SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)
Decitabine
Decitabine is a hypomethylating agent.
RECRUITING
Montefiore Medical Center, The Bronx
RECRUITING
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RECRUITING
Emory University, Atlanta
RECRUITING
Mayo Clinic, Jacksonville
RECRUITING
AdventHealth Medical Group & Bone Marrow Transplant at Orlando, Orlando
RECRUITING
University of Miami, Miami
RECRUITING
Moffitt Cancer Center, Tampa
Collaborators (2)
H. Lee Moffitt Cancer Center and Research Institute
OTHER
National Heart, Lung, and Blood Institute (NHLBI)
NIH
AdventHealth
OTHER
Emory University
OTHER
University of Miami
OTHER
Mayo Clinic
OTHER
Montefiore Medical Center
OTHER
National Cancer Institute (NCI)
NIH
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER
Syntrix Biosystems, Inc.
INDUSTRY